Related Experiment Video
Updated: Sep 10, 2025

Author Spotlight: Point-of-Care Ultrasound for Gastric Content Assessment and Risk Stratification in Perioperative Care
Published on: September 22, 2023
Effect of Oral Proton-Pump Inhibitor Administration on Reducing the Delayed Bleeding Risk in 5 Upper Gastrointestinal
Hiroko Abe1, Waku Hatta1, Kunio Tarasawa2
1Division of Gastroenterology, Tohoku University Graduate School of Medicine, Sendai, Japan.
Introduction:
Although proton-pump inhibitor (PPI) is often prescribed for reducing delayed bleeding in upper gastrointestinal endoscopic treatments, no studies with a sufficient sample size evaluated its reduced effect compared with the absence of acid-suppressive agents. The aim of this study was to investigate the effect of oral PPI on reducing delayed bleeding in 5 upper gastrointestinal endoscopic treatments.
Methods:
This population-based cohort study collected data from patients who were either prescribed with PPIs or received no acid-suppressive therapy and who underwent esophageal endoscopic mucosal resection (E-EMR), esophageal endoscopic submucosal dissection (E-ESD), gastric endoscopic mucosal resection (G-EMR), gastric endoscopic submucosal dissection (G-ESD), or percutaneous endoscopic gastrostomy (PEG) in Japan between 2012 and 2022 from the Diagnosis Procedure Combination database. The primary outcome was delayed bleeding in each procedure. We conducted propensity score matching to balance 2 comparison groups and performed logistic regression analyses to compare bleeding outcomes.
Results:
This study included data on 172,635 patients. After propensity score matching, the delayed bleeding risk with PPI use was significantly lower in G-EMR (odds ratio [OR], 0.66; 95% confidence interval [CI], 0.52-0.84) and G-ESD (OR, 0.39; 95% CI, 0.30-0.50). By contrast, a lower delayed bleeding risk of PPI was not observed in E-EMR (OR, 1.05; 95% CI, 0.56-1.99), E-ESD (OR, 1.09; 95% CI, 0.86-1.38), and PEG (OR, 1.03; 95% CI, 0.93-1.13). The subgroup and sensitivity analyses almost consistently confirmed the main results.
Discussion:
Oral PPI administration contributed to reducing delayed bleeding risk in G-EMR and G-ESD but not in E-EMR, E-ESD, and PEG.
Related Concept Videos
Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...
Peptic Ulcer Disease IV: Management
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
Acid Suppressive Drugs for Peptic Ulcer Disease: Histamine H2-Receptor Antagonists
Gastroesophageal Reflux Disease II: Clinical Features and Management
Clinical Manifestations
GERD presents itself in a multitude of ways, with symptoms varying from person to person. The hallmark symptoms are...
Endoscopic Procedures I: Esophagogastroduodenoscopy
During an EGD, the endoscope can be used to:

